News

Public · Published

TD Cowen maintains Alnylam Pharmaceuticals at Buy, lowers price target to $354 from $482

TD Cowen kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $354 from $482, a 26.6% decrease. The new target implies 103.4% upside from the October 29 close of $174.

Published:

Updated:

What happened

TD Cowen kept its Buy rating on Alnylam Pharmaceuticals but cut its price target to $354 from $482, a 26.6% decrease. The new target implies 103.4% upside from the October 29 close of $174.

Confirmed

Global impact / market context

A lower price target still above the current price signals the analyst sees less upside but keeps a positive view. Investors reading this may question whether expected profits or drug prospects are weaker than previously assumed.

Analyst inference

Other recent analyst targets for Alnylam range from $199 to $320, all above the $174 close. TD Cowen's $354 target sits above that range, so it stands out as more optimistic than peers even after the cut.

Analyst inference

What to watch

  1. TD Cowen's $354 target implies 103.4% upside from the October 29 close of $174, so the gap between the target and the share price is the key figure to track. Confirmed
  2. Watch whether other firms revise their Alnylam targets after TD Cowen's cut, since five recent notes already range from $199 to $320 and could move in response. Proposed
  3. Track Alnylam's coming revenue and research spending updates, because a lower target can reflect softer expected profit, higher costs, or delayed drug progress that would show up there. Analyst inference

Evidence

  • Original source link unavailable